A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation

Blood

Volumn 99, Issue 11, 2002, Pages 3993-3998

  Nogami, Keiji ^a,b,c   Shima, Midori ^a,b,c   Nishiya, Katsumi ^a,b,c   Hosokawa, Kazuya ^a,b,c   Saenko, Evgueni L ^a,b,c   Sakurai, Yoshihiko ^a,b,c   Shibata, Masaru ^a,b,c   Suzuki, Hiroshi ^a,b,c   Tanaka, Ichiro ^a,b,c   Yoshioka, Akira ^a,b,c  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Holland Laboratory ^*

^c HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; BINDING SITE; BLOOD CLOTTING; COMPETITIVE INHIBITION; CONTROLLED STUDY; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0036625005     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.11.3993     Document Type: Article

References (34)

1. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256:3433-3442.
2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330-337.
3. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature. 1984;312:342-347.
4. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342.
5. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505-512.
6. Walker FJ, Scandella D, Fay PJ. Identification of the binding site for activated protein C on the light chain of factor V and VIII. J Biol Chem. 1990;265:1484-1489.
7. Hoyer LW. The factor VIII complex: Structure and function. Blood. 1981;58:1-13.
8. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor; studies on post-transfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60:390-404.
9. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature. 1979;279:636-638.
10. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem. 1988;263:5230-5234.
11. Shima M, Yoshioka A, Nakai H, et al. Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor. Int J Hematol. 1991;54:515-522.
12. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240-246.
13. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem. 1994;269:11601-11605.
14. Saenko EL, Scandella D. The acidic region of the light chain and the C2 domain together form a high affinity binding site for von Willebrand factor. J Biol Chem. 1997;272:18007-18014.
15. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988;263:10451-10455.
16. Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000;95:156-163.
17. Andersson LO, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J. 1981;206:161-167.
18. O'Brien DP, Johnson D, Byfield P, Tuddenham EGD. Inactivation of factor VIII by factor IXa. Biochemistry. 1992;31:2805-2812.
19. Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000-31007.
20. Fay PJ, Coumans JV, Walker FJ. Von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem. 1991;266:2172-2177.
21. Nogami K, Shima M, Giddings JC, et al. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis. Blood. 2001;97:669-677.
22. Shima M, Yoshioka A, Yoshikawa N, et al. Enzyme-linked immunosorbent assay (ELISA) for von Willebrand factor antigen (VWF:AG) using monoclonal antibodies to von Willebrand factor. J Nara Med Assoc. 1986;31:672-679.
23. Gilbert GE, Furle BC, Furie B. Binding to human factor VIII to phospholipid vesicles. J Biol Chem. 1990;265:815-822.
24. Houghton RA. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci U S A. 1985;82:5131-5135.
25. Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS. Localization of the binding regions of a murine monoclonal antifactor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest. 1988;82:123-128.
26. Suzuki H, Shima M, Arai M, et al. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes. Thromb Haemost. 1997;77:862-867.
27. Jemmerson R, Margoliash E. Preparation of site-specific anti-cytochrome c antibodies and their application. Methods Enzymol. 1981;74:244-262.
28. Shima M, Fulcher CA, de Graaf Mahoney S, Houghten RA, Zimmerman TS. Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669. J Biol Chem. 1988;263:10198-10203.
29. Veltkamp JJ, Drion EF, Loeliger EA. Detection of the carrier state in hereditary coagulation disorders. Thromb Diath Haemorrh. 1968;19:279-286.
30. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood. 1984;63:486-489.
31. Koppelman SJ, van Hoelj M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood. 1996;87:2292-2300.
32. Hosokawa K, Ohnishi T, Shima M, Nagata M, Koide T. Preparation of anhydrothrombin and characterization of its interaction with normal thrombin substrates. Biochem J. 2001;354:309-313.
33. Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 1999;402:439-442.
34. Lenting PJ, Neels JG, van den Berg BMM, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274:23734-23739.